There have been recent reports in the press and media concerning difficulties in accessing to medicines in Turkey, and the country’s research-based pharma association, the AiFD, says it has received various inquiries regarding the matter.
Although the association is not involved in procurement of individual medicinal products, it notes that the pharmaceutical sector is making great sacrifices to prevent patients from experiencing any difficulties in accessing medicines. However, price regulations introduced in recent years and ongoing policies do give rise to such a risk, as the AiFD has repeatedly warned in the past, both individually and jointly with other sector organizations, by its previous public statements on November 2011, (AÄ°FD, Ä°EÄ°S and TÄ°SD Joint Press Release), November 26, 2011, December 22, 2011 (AÄ°FD, Ä°EÄ°S and TÄ°SD Joint Statement), December 27, 2011, and January 12, 2012, which are available on the official website of AÄ°FD.
No price increases approved, despite negative exchange rate changes
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze